S Salekzamani1, H Mehralizadeh2, A Ghezel1, Y Salekzamani3, M A Jafarabadi4, A S Bavil5, B P Gargari6. 1. Student Research Committee, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Student Research Committee, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Physical Medicine and Rehabilitation Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Road Traffic Injury Research Center, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Golgasht St., Attar Neyshapouri Av., 5166614, Tabriz, Iran. pourghassemb@tbzmed.ac.ir.
Abstract
PURPOSE: The evidence in support of the effect of vitamin D deficiency on cardiovascular diseases is inconsistent. The objective of this randomized, controlled, double-blind study was to assess the effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome. METHODS:Eighty subjects were randomized to receive 50,000 IU vitamin D or matching placebo weekly for 16 weeks. Fasting blood sugar, homeostasis model assessment of insulin resistance, insulin sensitivity (Quicki), serum lipid profiles (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride (TG) and total cholesterol), anthropometric factors and blood pressure were assessed before and after intervention. Dietary intake and sun exposure were also determined. The trial was registered at http://www.irct.ir (code: IRCT201409033140N14). RESULTS:Participants were 40.49 ± 5.04 years and 49 % male. All of the intervention group and 97 % of placebo group were vitamin D deficient or insufficient (25-hydroxyvitamin D <75 nmol/L). After intervention, serum 25(OH)D concentration was increased by 61.93 nmol/L in intervention group, while it was decreased in placebo group (p < 0.001). There was a significant change in TG concentration after 4 months (p < 0.001). Other metabolic or anthropometric factors did not change significantly (p = 0.05). CONCLUSION: Supplementation with high-dose vitamin D for 4 months improved vitamin D status and decreased TG levels in subjects with metabolic syndrome. However, it did not have any beneficial effects on other cardiometabolic risk factors; this might be due to the inadequate vitamin D status attained in this study which was conducted in a severely deficient region.
RCT Entities:
PURPOSE: The evidence in support of the effect of vitamin D deficiency on cardiovascular diseases is inconsistent. The objective of this randomized, controlled, double-blind study was to assess the effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome. METHODS: Eighty subjects were randomized to receive 50,000 IU vitamin D or matching placebo weekly for 16 weeks. Fasting blood sugar, homeostasis model assessment of insulin resistance, insulin sensitivity (Quicki), serum lipid profiles (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride (TG) and total cholesterol), anthropometric factors and blood pressure were assessed before and after intervention. Dietary intake and sun exposure were also determined. The trial was registered at http://www.irct.ir (code: IRCT201409033140N14). RESULTS:Participants were 40.49 ± 5.04 years and 49 % male. All of the intervention group and 97 % of placebo group were vitamin Ddeficient or insufficient (25-hydroxyvitamin D <75 nmol/L). After intervention, serum 25(OH)D concentration was increased by 61.93 nmol/L in intervention group, while it was decreased in placebo group (p < 0.001). There was a significant change in TG concentration after 4 months (p < 0.001). Other metabolic or anthropometric factors did not change significantly (p = 0.05). CONCLUSION: Supplementation with high-dose vitamin D for 4 months improved vitamin D status and decreased TG levels in subjects with metabolic syndrome. However, it did not have any beneficial effects on other cardiometabolic risk factors; this might be due to the inadequate vitamin D status attained in this study which was conducted in a severely deficient region.
Entities:
Keywords:
Anthropometry; Cardiometabolic factors; Lipid profile; Metabolic syndrome; Vitamin D
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2012-03-22 Impact factor: 5.958
Authors: Donald Liu; Bernadette O Fernandez; Alistair Hamilton; Ninian N Lang; Julie M C Gallagher; David E Newby; Martin Feelisch; Richard B Weller Journal: J Invest Dermatol Date: 2014-01-20 Impact factor: 8.551
Authors: Sara A Chacko; Yiqing Song; JoAnn E Manson; Linda Van Horn; Charles Eaton; Lisa W Martin; Anne McTiernan; J David Curb; Judith Wylie-Rosett; Lawrence S Phillips; Raymond A Plodkowski; Simin Liu Journal: Am J Clin Nutr Date: 2011-05-25 Impact factor: 7.045
Authors: Amena Sadiya; Solafa M Ahmed; Martin Carlsson; Yohannes Tesfa; Mary George; Samia H Ali; Hisham H Siddieg; Salah Abusnana Journal: Clin Nutr Date: 2015-03-24 Impact factor: 7.324
Authors: R Fornari; D Francomano; E A Greco; C Marocco; C Lubrano; F Wannenes; V Papa; V M Bimonte; L M Donini; A Lenzi; A Aversa; S Migliaccio Journal: J Endocrinol Invest Date: 2014-10-29 Impact factor: 4.256
Authors: Armin Zittermann; Sabine Frisch; Heiner K Berthold; Christian Götting; Joachim Kuhn; Knut Kleesiek; Peter Stehle; Heinrich Koertke; Reiner Koerfer Journal: Am J Clin Nutr Date: 2009-03-25 Impact factor: 7.045
Authors: Weihua Yuan; Wei Pan; Juan Kong; Wei Zheng; Frances L Szeto; Kari E Wong; Ronald Cohen; Anna Klopot; Zhongyi Zhang; Yan Chun Li Journal: J Biol Chem Date: 2007-08-09 Impact factor: 5.157